People with high-risk early breast cancer are increasingly treated with CDK4/6 inhibitors alongside endocrine therapy. These treatments improve outcomes but can cause side effects such as fatigue, diarrhea, and low white blood counts. As a result, patients require...
Bright Run funded projects
A population-level approach for implementing rehabilitation for individuals with breast cancer at the Juravinski Cancer Centre: a feasibility trial
Many people, living with and beyond breast cancer, experience challenges such as pain, fatigue, weakness, and difficulty returning to everyday activities. Rehabilitation services, such as physiotherapy, can help address these challenges, but not everyone who could...
Tumour-informed ctDNA detection in high-risk early breast cancer: a pilot feasibility study
Some patients with early breast cancer receive chemotherapy before surgery to shrink the tumour. After surgery, doctors examine the tissue to see whether any cancer remains. If it does, that patient has a higher chance of the disease coming back, so additional...
Co-design, implementation, and mixed-methods evaluation of a theory
Informed audit and feedback program for breast cancer specialists within a learning health system Breast cancer care involves many complex decisions, including surgery, drug treatment, radiation, and genetic testing. Although clear guidelines exist, patients do not...
Radiation omission in patients with clinically node negative
Breast cancer undergoing lumpectomy and with a pathologic complete response to neoadjuvant chemotherapy (ROSALIE) Some women with early-stage breast cancer are treated with chemotherapy before having surgery. For many women, chemotherapy works so well there are no...
CNV-DNA methylation crosstalk and PWP2-mediated
Translational reprogramming drive aggressive triple-negative breast cancer phenotypes in women of African ancestry Breast cancer does not affect all women equally. Black women (of African ancestry, WAA) are more likely to develop an aggressive form of breast cancer...





